A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis
A Phase 2 Study, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy, Tolerability, and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy
Sponsor: Kadmon Corporation, LLC
This PHASE2 trial investigates Chronic Plaque Psoriasis and is currently completed. Kadmon Corporation, LLC leads this study, which shows 15 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 10 earlier versions
-
Oct 2021 — Nov 2021 [monthly]
Completed PHASE2
-
May 2021 — Oct 2021 [monthly]
Completed PHASE2
-
Jan 2021 — May 2021 [monthly]
Completed PHASE2
-
May 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jul 2019 — May 2020 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jun 2018 — Jul 2019 [monthly]
Recruiting PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Mar 2017 — Aug 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kadmon Corporation, LLC
For direct contact, visit the study record on ClinicalTrials.gov .